The Significance of Funguria in Hospitalized Patients

Urinary Tract Infections Clinical Trial

— FACES  

Official title:

The Significance of Funguria in Hospitalized Patients (FACES)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00787085
• Other study ID #: 10024-05
• Secondary ID: NIH-AI01831
• Status: Completed
• Phase: N/A
• First received: November 6, 2008
• Last updated: November 6, 2008
• Start date: September 2001
• Est. completion date: February 2006

Study information

• Verified date: November 2008
• Source: Los Angeles Biomedical Research Institute
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review BoardUnited States: Federal Government
• Study type: Observational

Clinical Trial Summary

This investigation is a epidemiologic case-control study of the risk factors associated with nosocomial funguria (fungi in the urine).

Description:

A recent large multi-center national surveillance survey of almost 5000 nosocomial (hospital based) urine isolates from medical intensive care units demonstrated that fungi comprised nearly 40% of urine isolates. Little is known about distinguishing fungi that cause colonization from those causing infection.

The objective of this study is to define the epidemiology of nosocomial funguria and natural history of patients that develop funguria while hospitalized.

Patients who may have eligible for this study will be identified from microbiology laboratory specimens at the Harbor-UCLA Medical Center and Cedars-Sinai Medical Center.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 919
• Est. completion date: February 2006
• Est. primary completion date: February 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients hospitalized at least 12 hours of any age (< 1 day to > 100 years of age) AND a urine or blood culture positive for fungi, OR urine culture negative for fungi (control group)

Exclusion Criteria:

• Patients already surveyed for funguria during current hospitalization and patients already being followed for recognized funguria

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Urinary Tract Infections

Locations

Country	Name	City	State
United States	Cedars-Sinai Medical Center	Los Angeles	California
United States	Harbor-UCLA Medical Center	Torrance	California

Sponsors (3)

Lead Sponsor	Collaborator
Los Angeles Biomedical Research Institute	Cedars-Sinai Medical Center, National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Funguria		Hospitalization day 0, 3, 7, 14, and every 7 days thereafter until hospital discharge or death	No